| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/25/2001 | CA2379319A1 Aminobenzophenones as inhibitors of il-1.beta. and tnf-.alpha. |
| 01/25/2001 | CA2379316A1 Novel aminobenzophenones |
| 01/25/2001 | CA2379293A1 Aminobenzophenones as inhibitors of il-1.beta. and tnf-.alpha. |
| 01/25/2001 | CA2379286A1 Aminobenzophenones as inhibitors of il-1.beta. and tnf-.alpha. |
| 01/25/2001 | CA2379273A1 Aminobenzophenones as inhibitors of il-1.beta. and tnf-.alpha. |
| 01/25/2001 | CA2379064A1 Bradykinin b1 receptor antagonists |
| 01/25/2001 | CA2378930A1 Electron transfer proteins |
| 01/25/2001 | CA2378430A1 Methods and apparatus for preparation of lipid vesicles |
| 01/25/2001 | CA2378026A1 Novel glycosyl sulfotransferases gst-4.alpha., gst-4.beta., and gst-6 |
| 01/25/2001 | CA2377247A1 Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor |
| 01/25/2001 | CA2375954A1 Alpha-hydroxy-gamma-¬¬(carbocyclic-or heterocyclic-substituted)amino|carbonyl|alkanamide derivatives and uses thereof |
| 01/25/2001 | CA2375458A1 Compositions and methods for the treatment of immune related diseases |
| 01/25/2001 | CA2340721A1 Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor |
| 01/24/2001 | EP1070727A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction |
| 01/24/2001 | EP1070502A2 Compositions and methods for treating or preventing inflammatory diseases |
| 01/24/2001 | EP1070254A1 Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions |
| 01/24/2001 | EP1070253A1 Use of ror receptors for screening substances useful for the treatment of atherosclerosis |
| 01/24/2001 | EP1070140A1 Compositions and methods for treating cells having double minute dna |
| 01/24/2001 | EP1070129A2 Dadd, death activator death domain protein |
| 01/24/2001 | EP1070123A2 Herpes simplex virus latency associated transcript polypeptides |
| 01/24/2001 | EP1070080A1 HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE |
| 01/24/2001 | EP1070064A1 Antagonists of gonadotropin releasing hormone |
| 01/24/2001 | EP1070047A2 Lipids |
| 01/24/2001 | EP1069917A1 Novel complementing receptor-ligand pairs and adoptive immunotherapy using same |
| 01/24/2001 | EP1069911A1 A novel nitroreductase and therapeutic uses therefor |
| 01/24/2001 | EP1069906A1 Conjugates useful in the treatment of prostrate cancer |
| 01/24/2001 | EP1069897A1 Methods for inhibiting mrp1 |
| 01/24/2001 | EP1069890A1 Incorporation of active substances in carrier matrixes |
| 01/24/2001 | EP1069883A1 Cholesterol sulfate compositions for enhancement of stratum corneum function |
| 01/24/2001 | EP0788513B1 Use of binding agents to cd23 in the treatment of autoimmune diseases |
| 01/24/2001 | CN1281468A Treatment with anti-ErbB2 antibodies |
| 01/24/2001 | CN1281431A Urethanes, thio and dithio analogues, salts thereof, medicaments containing said compounds, use and method for production thereof |
| 01/24/2001 | CN1281367A Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| 01/24/2001 | CN1281363A Progestogen-antiprogestogen regimens |
| 01/24/2001 | CN1281362A Novel combination medicine |
| 01/24/2001 | CN1281361A Use of aromatase inhibitor in treatment of uropoiesis disease and method for studying uropoiesis disease |
| 01/24/2001 | CN1281359A Use of thiazolidinediones for treatment of hyperglycaemia |
| 01/24/2001 | CN1281358A Use of thiazolidinediones for treatment of hyperglycaemia |
| 01/24/2001 | CN1281357A Medicaments |
| 01/24/2001 | CN1281335A Treatment of schizophrenia with ampakines and neuroleptics |
| 01/24/2001 | CN1281334A Method for treating Alzheimer's disease |
| 01/23/2001 | US6177478 Using an amine polymer; prevent kidney stones |
| 01/23/2001 | US6177460 Using a n-chlorophenyl(thio)carbamate |
| 01/23/2001 | US6177455 Administering a nitrogen-containing heterocyclic compound |
| 01/23/2001 | US6177450 Synergizing combination having an antagonist effect on NKI and NK2 receptors |
| 01/23/2001 | US6177428 Treatment of sexual dysfunction; stimulation of endogenous nitrogen monoxide synthesis |
| 01/22/2001 | CA2746824A1 Neurotherapeutic composition and method |
| 01/18/2001 | WO2001004354A2 Use of ras inhibitors of inhibiting muscle atrophy |
| 01/18/2001 | WO2001004349A2 Method for the diagnosis or the prognosis of alzheimer disease therapeutical composition for preventing or treating alzheimer disease |
| 01/18/2001 | WO2001004326A1 Tankyrase homolog protein (thp), nucleic acids, and methods related to the same |
| 01/18/2001 | WO2001004318A2 Myxoma virus genes for immune modulation |
| 01/18/2001 | WO2001004308A1 Human lim domain proteins |
| 01/18/2001 | WO2001004305A2 Human proteins involved in detoxification |
| 01/18/2001 | WO2001004303A1 Compositions corresponding to a calcium transporter and methods of making and using same |
| 01/18/2001 | WO2001004282A2 Replication-competent anti-cancer vectors |
| 01/18/2001 | WO2001004269A1 Ligands for use in therapeutic compositions for the treatment of hemostasis disorders |
| 01/18/2001 | WO2001004157A2 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS |
| 01/18/2001 | WO2001004133A1 Human eag2 |
| 01/18/2001 | WO2001004119A1 Amido spiropiperidines promote the release of growth hormone |
| 01/18/2001 | WO2001003774A2 Pharmaceutical composition for the treatment of calcification |
| 01/18/2001 | WO2001003743A1 Manipulation of tissue or organ type using the notch pathway |
| 01/18/2001 | WO2001003734A1 Blocking immune response to a foreign antigen using an antagonist which binds to cd20 |
| 01/18/2001 | WO2001003720A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | WO2001003716A1 Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
| 01/18/2001 | WO2001003709A1 Calcium-containing structures and methods of making and using the same |
| 01/18/2001 | WO2001003707A1 Heartburn treatment |
| 01/18/2001 | WO2001003705A1 Compositions and methods for raising hdl cholesterol levels |
| 01/18/2001 | WO2001003699A1 Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances |
| 01/18/2001 | WO2001003692A1 Compositions and methods for promoting nerve regeneration |
| 01/18/2001 | WO2001003688A2 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 01/18/2001 | WO2001003687A2 Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans |
| 01/18/2001 | WO2001003684A2 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
| 01/18/2001 | WO2001003682A2 Use of pyridoxin derivatives for the treatment of diabetes and related complications |
| 01/18/2001 | WO2001003669A2 Delivery of liposomal-encapsulated antioxidants and applications thereof |
| 01/18/2001 | WO2001003659A1 Use of rar antagonists as modulators of hormone mediated processes |
| 01/18/2001 | WO2000066099A3 Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
| 01/18/2001 | WO2000063415A8 Dna encoding the human vanilloid receptor vr1 |
| 01/18/2001 | WO2000062743A3 Skin care compositions containing combination of skin care actives |
| 01/18/2001 | WO2000056864A3 Methods for altering substrate specificity of phosphoinositide-dependent-protein kinase 1 (pdk1) |
| 01/18/2001 | WO2000055180A3 Human lung cancer associated gene sequences and polypeptides |
| 01/18/2001 | WO2000047723A3 Human diacylglycerol kinase beta (hdagk beta) proteins and nucleotide sequences encoding the same |
| 01/18/2001 | WO2000043014A8 Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections |
| 01/18/2001 | WO2000040227A3 Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| 01/18/2001 | WO2000037067A3 Sensitizing agents for the treatment of skin lesions |
| 01/18/2001 | WO2000032825A3 Development of anti-microbial agents based on bacteriophage genomics |
| 01/18/2001 | WO2000019210A3 Determining the mechanism of beta-amyloid peptide generation |
| 01/18/2001 | DE19932555A1 Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen Drugs with a protective effect against oxidative-toxic and in particular against cardiotoxic substances |
| 01/18/2001 | CA2381125A1 Ligands for use in therapeutic compositions for the treatment of hemostasis disorders |
| 01/18/2001 | CA2379373A1 Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and .beta.1 integrins |
| 01/18/2001 | CA2379274A1 Blocking immune response to a foreign antigen using an antagonist which binds to cd20 |
| 01/18/2001 | CA2379133A1 Human proteins involved in detoxification |
| 01/18/2001 | CA2378989A1 Human lim domain proteins |
| 01/18/2001 | CA2378982A1 Methods of inhibiting muscle atrophy |
| 01/18/2001 | CA2378610A1 Human eag2 |
| 01/18/2001 | CA2378567A1 Novel myxoma genes for immune modulation |
| 01/18/2001 | CA2378515A1 Compositions corresponding to a calcium transporter and methods of making and using same |
| 01/18/2001 | CA2378465A1 Manipulation of tissue or organ type using the notch pathway |
| 01/18/2001 | CA2378402A1 Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
| 01/18/2001 | CA2378179A1 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | CA2378018A1 Heartburn treatment |